| 3 Monster Stocks in the Making |
Think of some of the biggest and most successful stocks on the market. Now, go back 20 or 30 years. |
fool.com |
2025-05-11 15:15:00 |
Czytaj oryginał (ang.) |
| Why Viking Therapeutics Stock Surged Nearly 20% Higher in April |
One of the best catalysts for a stock's rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics' (VKTX 0.32%) stock in April. |
fool.com |
2025-05-06 08:33:31 |
Czytaj oryginał (ang.) |
| Why Viking Therapeutics Stock Was Victorious This Week |
Viking Therapeutics (VKTX 2.85%), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, was a winning stock this week. Over the course of the past five trading days, its price rose by almost 18%, according to data compiled by S&P Global Market Intelligence. |
fool.com |
2025-05-02 21:48:53 |
Czytaj oryginał (ang.) |
| Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday |
Positive jobs news and positive rumors out of China are lifting stock markets today, as the U.S. Labor Department reports adjusted nonfarm payrolls grew by 177,000 jobs in April, and CNBC reports that China may be "evaluating the possibility of starting trade negotiations" that could abbreviate a trade war with the U.S. |
fool.com |
2025-05-02 15:55:45 |
Czytaj oryginał (ang.) |
| Where Will Viking Therapeutics Be in 3 Years? |
The pharmaceutical and biotechnology business tends to be about hitting home runs more than just getting on base. A highly successful drug, sometimes referred to as a blockbuster, can build up a small developer into a mainstream competitor. |
fool.com |
2025-05-02 08:20:00 |
Czytaj oryginał (ang.) |
| 1 Beaten-Down Stock to Buy and Hold for 10 Years |
Viking Therapeutics (VKTX 3.44%) was one of the hottest biotech stocks of 2024; its shares soared last year following excellent clinical progress. However, things have been very different in 2025, at least so far: Its stock is down by 35% year to date due to a combination of factors. |
fool.com |
2025-05-01 09:47:00 |
Czytaj oryginał (ang.) |
| Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain |
Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth treatment areas: and that's weight loss. Analysts forecast a compound annual growth rate in the double digits from today over the next several years, with the market reaching $100 billion to $130 billion in the early 2030s. |
fool.com |
2025-04-30 07:15:00 |
Czytaj oryginał (ang.) |
| Why Viking Therapeutics Stock Popped Again Today |
Shares of Viking Therapeutics (VKTX 11.41%) jumped 12.5% through 11:40 a.m. ET on Tuesday on further support from Wall Street analysts. |
fool.com |
2025-04-29 16:24:30 |
Czytaj oryginał (ang.) |
| Why Viking Therapeutics Stock Popped Today |
Viking Therapeutics (VKTX 0.40%) stock inched 2.3% higher through 10:20 a.m. ET Monday, and for a most curious reason. |
fool.com |
2025-04-28 15:06:58 |
Czytaj oryginał (ang.) |
| Viking Therapeutics Stock May Struggle After As-Expected Report |
Viking Therapeutics Inc. NASDAQ: VKTX reported earnings after the market closed on Apr. 23. The stock is pushing higher as investors attempt to sort out a report that delivered no real news that investors hadn't heard. |
marketbeat.com |
2025-04-25 12:02:32 |
Czytaj oryginał (ang.) |
| Viking Therapeutics: Q1 Earnings Overview - Hard To Understand Wall Street's Pessimism |
Viking Therapeutics' VK2735, a GLP-1 candidate, has driven significant share price gains but faces stiff competition from Eli Lilly and Novo Nordisk. Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future trials. VK2735's subcutaneous and oral formulations show promising weight loss results and safety, with Phase 3 and Phase 2 trials soon to be underway. |
seekingalpha.com |
2025-04-24 12:58:42 |
Czytaj oryginał (ang.) |
| Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips |
VKTX's first-quarter earnings miss estimates. The company remains on track to start the late-stage development of its obesity injection before June-end. |
zacks.com |
2025-04-24 11:35:40 |
Czytaj oryginał (ang.) |
| Viking Therapeutics, Inc. (VKTX) Q1 2025 Earnings Call Transcript |
Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q1 2025 Results Conference Call April 23, 2025 4:30 PM ET Company Participants Stephanie Diaz - Manager, Investor Relations Brian Lian - President and Chief Executive Officer Greg Zante - Chief Financial Officer Conference Call Participants Asim Rana - Truist Securities Mike Ulz - Morgan Stanley Ryan Deschner - Raymond James Jay Olson - Oppenheimer Hardik Parikh - JPMorgan Mayank Mamtani - B. Riley Securities Annabel Samimy - Stifel Roger Song - Jefferies Andy Hsieh - William Blair Biren Amin - Piper Sandler Thomas Smith - Leerink Partners George Farmer - Scotiabank Yale Jen - Laidlaw & Company Jeet Mukherjee - BTIG Operator Welcome to the Viking Therapeutics First Quarter 2025 Financial Results Conference Call. |
seekingalpha.com |
2025-04-23 23:46:03 |
Czytaj oryginał (ang.) |
| Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update |
Conference call scheduled for 4:30 p.m. ET today Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25 Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully Enrolled; Data Expected 2H25 Broad Manufacturing Agreement with CordenPharma to Support Future Commercialization of VK2735 Strong Quarter-End Cash Position of $852 Million SAN DIEGO , April 23, 2025 /PRNewswire/ --Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2025, and provided an update on its clinical pipeline and other corporate developments. |
prnewswire.com |
2025-04-23 20:05:00 |
Czytaj oryginał (ang.) |
| Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? |
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? |
zacks.com |
2025-04-22 14:36:53 |
Czytaj oryginał (ang.) |
| Is Viking Therapeutics Stock (VKTX) Nearing A Bottom? |
With earnings scheduled for the 23rd, Viking Therapeutic's (NASDAQ: VKTX) first-quarter investor call is expected to center around key pipeline updates. The spotlight will be on three clinical candidates: VK2735 (targeting obesity), VK2809 (for non-alcoholic steatohepatitis, or NASH), and VK0214 (for X-linked adrenoleukodystrophy, or X-ALD). |
seeitmarket.com |
2025-04-22 03:39:45 |
Czytaj oryginał (ang.) |
| Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know |
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $23.94, representing a +1.44% change from its previous close. |
zacks.com |
2025-04-17 22:56:17 |
Czytaj oryginał (ang.) |
| 2 Stocks Down by 25% or More This Year to Buy and Hold |
Equity markets have had a rough go of it this year due to President Trump's macroeconomic policies. Though it can be challenging to navigate this environment, one way to make the best of it is to look for terrific stocks to invest in while they are down. |
fool.com |
2025-04-17 14:00:00 |
Czytaj oryginał (ang.) |
| Viking Therapeutics: A Lot More Compelling After The Meltdown - Initiating Cautious Buy (Rating Upgrade) |
VKTX's deep selloff from the 2024 heights have been well warranted indeed, given its pre-revenue status and ongoing cash burn, despite the promising GLP-1 candidates. It has also triggered the improved margin of safety and relatively compelling 2030 valuations, despite the recently downgraded forward estimates. This is significantly aided by the improved clarity surrounding VKTX's go-to-market strategy, as the management announces its first supply and manufacturing partnership. |
seekingalpha.com |
2025-04-17 13:30:00 |
Czytaj oryginał (ang.) |
| Viking Therapeutics Stock Pops But Struggles to Hold Gains |
Viking Therapeutics Inc. NASDAQ: VKTX has taken investors on a wild ride since the beginning of 2024. At one point, VKTX stock was up 375% from its closing price on January 2, 2024. |
marketbeat.com |
2025-04-16 14:33:06 |
Czytaj oryginał (ang.) |
| Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval? |
The GLP-1 industry is currently an oligopoly ruled by two pharmaceutical giants, Novo Nordisk A/S NYSE: NVO, maker of semaglutide under the Ozempic and Wegovy name brands, and Eli Lilly & Co. NYSE: LLY, maker of tirzepatide and dual GLP-1/GIP agonist treatment sold under Mounjaro and Zepbound name brands. As compounding facilities cease making compounded versions of their drugs, which are no longer on the FDA drug shortage list, the medical sector oligopoly will likely regain many more users to seal their dominance. |
marketbeat.com |
2025-02-26 09:50:14 |
Czytaj oryginał (ang.) |
| Is Viking Therapeutics a Buy Right Now? |
Viking Therapeutics (VKTX -3.01%) soared into the spotlight about a year ago when it delivered promising data on a drug candidate that aims to compete in an area of very high demand: weight loss. The stock surged more than 120% in one trading session after Viking spoke about VK2735, a candidate that works in the same way as big pharma Eli Lilly's blockbuster drugs Mounjaro and Zepbound. |
fool.com |
2025-02-26 06:20:00 |
Czytaj oryginał (ang.) |
| Viking Therapeutics: Development Of VK2735 Continues, Buyout Or Not |
Viking Therapeutics: Development Of VK2735 Continues, Buyout Or Not |
seekingalpha.com |
2025-02-24 22:16:37 |
Czytaj oryginał (ang.) |
| Should You Buy VKTX Stock Amid Renewed M&A Speculations? |
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics, regardless of buyout speculations. |
zacks.com |
2025-02-24 12:45:25 |
Czytaj oryginał (ang.) |
| Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk |
Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as the largest drugmaker in the world, with a market cap of $844 billion, after its shares skyrocketed more than 270%. |
fool.com |
2025-02-24 06:52:00 |
Czytaj oryginał (ang.) |
| 3 Weight-Loss Drug Stocks to Watch |
Weight-loss drugs have been popular over the past couple of years, and Hims & Hers Health Inc (NYSE:HIMS), Novo Nordisk A/S ( NYSE:NVO) , and Viking Therapeutics Inc (NASDAQ:VKTX) are among the most recognized names in the industry. |
schaeffersresearch.com |
2025-02-13 14:36:06 |
Czytaj oryginał (ang.) |
| 2 Stocks to Buy With Less Than $40 |
Some think investing in stocks requires substantial start-up capital, but that's false. Even with a modest sum, like $40, investors can acquire shares of companies whose long-term prospects look exciting, and all for the price of a few breakfast items. |
fool.com |
2025-02-10 11:00:00 |
Czytaj oryginał (ang.) |
| 3 No-Brainer Healthcare Stocks to Buy With $200 Right Now |
Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative biotech that may launch game-changing products down the road. |
fool.com |
2025-02-10 06:20:00 |
Czytaj oryginał (ang.) |
| 2 Stocks That Could Soar Again in 2025 |
Many companies in the biotech industry performed well last year. Two in particular stood out: Viking Therapeutics (VKTX 3.50%) and Summit Therapeutics (SMMT -2.71%). |
fool.com |
2025-02-08 10:50:00 |
Czytaj oryginał (ang.) |
| Down 65%, Is Viking Therapeutics Stock a Buy on the Dip? |
Nearly a year ago, Viking Therapeutics (VKTX 3.50%) shares exploded higher after the clinical-stage drugmaker announced successful results from a clinical trial with an experimental weight loss drug. |
fool.com |
2025-02-08 05:57:00 |
Czytaj oryginał (ang.) |
| VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10% |
Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline. |
zacks.com |
2025-02-06 11:25:23 |
Czytaj oryginał (ang.) |
| Has the Bubble Burst for Viking Therapeutics Stock? |
The excitement surrounding Viking Therapeutics (VKTX 3.49%) stock has been dying down significantly lately. In six months, the stock has lost more than 40% of its value. |
fool.com |
2025-02-06 10:15:00 |
Czytaj oryginał (ang.) |
| Viking Therapeutics Plummeted 10% On Its Earnings Report. Here's Why. |
Viking Therapeutics stock plunged late Wednesday on an earnings report that included mostly incremental updates for its weight-loss drugs. The post Viking Therapeutics Plummeted 10% On Its Earnings Report. |
investors.com |
2025-02-05 23:08:37 |
Czytaj oryginał (ang.) |
| Viking Therapeutics, Inc. (VKTX) Q4 2024 Earnings Conference Call Transcript |
Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q4 2024 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Stephanie Diaz - IR Manager Brian Lian - CEO and President Greg Zante - CFO Conference Call Participants Ryan Deschner - Raymond James Mike Ulz - Morgan Stanley Asim Rana - Truist Securities Jay Olson - Oppenheimer Annabel Samimy - Stifel Mayank Mamtani - B. Riley Securities Biren Amin - Piper Sandler Hardik Parikh - JPMorgan Andy Hsieh - William Blair Yale Jen - Laidlaw & Company Justin Zelin - BTIG Operator Welcome to the Viking Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call. |
seekingalpha.com |
2025-02-05 21:21:04 |
Czytaj oryginał (ang.) |
| Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update |
Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial Evaluating VK2735 in Obesity Underway Strong Year-End Cash Position of $903 Million SAN DIEGO , Feb. 5, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2024, and provided an update on its clinical pipeline and other corporate developments. |
prnewswire.com |
2025-02-05 18:05:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? |
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? |
zacks.com |
2025-02-05 12:30:47 |
Czytaj oryginał (ang.) |
| Prediction: This Pharma Stock Will Be the Best Performer in 2025 |
Market uncertainty can make nervous investors leery of investing in industries that are more speculative in nature, such as pharmaceuticals and biotechnology. |
247wallst.com |
2025-02-05 10:45:35 |
Czytaj oryginał (ang.) |
| Viking Therapeutics: Why The Oral VK2735 Phase 2 Readout Could Send The Stock Soaring |
Oral VK2735 is strategically positioned to become a best-in-class oral GLP-1 therapy, with the Phase 2 trial data readout in H2 2025 serving as a critical catalyst. Phase 1 data for VK2735 represents the best efficacy and safety profile ever reported for an oral GLP-1 drug. The oral obesity market is projected to be the fastest-growing segment within the broader weight-loss market, driven by the superior convenience of oral formulations compared to injectable treatments. |
seekingalpha.com |
2025-02-05 05:34:44 |
Czytaj oryginał (ang.) |
| This Weight Loss Stock Could Soar Over 220%, According to Wall Street. Time to Buy? |
Medications known as glucagon-like peptide 1 (GLP-1) receptor agonists are taking over the healthcare industry. While you may not be familiar with the term "GLP-1," I'd wager you'll recognize some of the most popular ones on the market today, including Ozempic, Wegovy, Mounjaro, and Zepbound. |
fool.com |
2025-02-02 08:36:00 |
Czytaj oryginał (ang.) |
| Viking Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy? |
Since VKTX is devoid of marketed drugs, investors will focus on pipeline updates when it reports Q4 results next week. |
zacks.com |
2025-01-30 10:21:07 |
Czytaj oryginał (ang.) |
| Why Viking Therapeutics Stock Plummeted by 24% in December |
Viking Therapeutics (VKTX 4.30%) didn't exactly capture investors' hearts in the final month of 2024. The biotech company's share price eroded by 24% in December, primarily on the back of a rival's aggressive move into a potentially very lucrative segment of the pharmaceutical market. |
fool.com |
2025-01-04 18:23:18 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX |
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2025-01-03 14:00:00 |
Czytaj oryginał (ang.) |
| Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? |
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? |
zacks.com |
2025-01-03 12:46:37 |
Czytaj oryginał (ang.) |
| Should You Buy the Dip on This High-Flying Stock? |
It's been an excellent year for Viking Therapeutics (VKTX 2.19%), a mid-cap biotech company. Thanks to impressive mid-stage clinical results, its stock skyrocketed in February. |
fool.com |
2025-01-03 10:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX |
NEW YORK , Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-01-02 12:20:00 |
Czytaj oryginał (ang.) |
| VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip? |
Despite the rising competition in the obesity space, we believe that there is room for smaller biotechs like Viking Therapeutics to grab a share of this booming market. |
zacks.com |
2025-01-02 09:21:35 |
Czytaj oryginał (ang.) |
| Viking Therapeutics, Inc. (VKTX) Advances While Market Declines: Some Information for Investors |
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $40.25, indicating a +1.19% shift from the previous trading day. |
zacks.com |
2024-12-31 20:55:52 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX |
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-31 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX |
NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-30 15:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX NEW YORK, December 27, 2024 (PRNEWSWIRE)Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-29 15:07:00 |
Czytaj oryginał (ang.) |
| 3 Stocks That Could Be Monster Winners in 2025 |
What do many kids like most about the coming of a new year? The fireworks. |
fool.com |
2024-12-29 08:47:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX |
NEW YORK , Dec. 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-12-27 18:35:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX |
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-26 19:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX |
NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-12-24 18:00:00 |
Czytaj oryginał (ang.) |
| Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck? |
The weight-loss biotech Viking Therapeutics (VKTX 1.83%) saw its stock get absolutely slammed on Dec. 18, falling 18% as a result of a new move announced by Merck (MRK -1.48%). |
fool.com |
2024-12-21 08:26:00 |
Czytaj oryginał (ang.) |
| My Top 10 Stocks to Buy for 2025 |
It's that time of year again. I'm not referring to buying gifts and preparing holiday meals -- although that may be part of your agenda too. |
fool.com |
2024-12-21 06:05:00 |
Czytaj oryginał (ang.) |
| Why Viking Therapeutics Tumbled by More Than 10% This Week |
News of a fresh licensing deal by a well-capitalized rival sent Viking Therapeutics (VKTX 1.83%) stock into something of a tailspin this week. According to data compiled by S&P Global Market Intelligence, the biotech's share price fell by just over 10% over the period as a result. |
fool.com |
2024-12-20 20:32:30 |
Czytaj oryginał (ang.) |
| Viking Therapeutics: Competition Fears Are Exaggerated |
Viking Therapeutics' VK2735 reported promising results in February, with significant weight loss, however, shares have returned to prices before reporting VENTURE Phase II results. The company's pipeline includes VK2809 for NASH, adding value beyond VK2735's weight-loss potential. Competition concerns are overblown; Viking's dual GLP-1/GIP agonist has competitive advantages over single-mechanism therapeutics, and concern regarding small-molecule candidates is as yet unfounded. |
seekingalpha.com |
2024-12-19 13:55:42 |
Czytaj oryginał (ang.) |
| Viking Therapeutics: Holiday Gift |
Viking Therapeutics has seen a significant drop, losing 50% in value since late October, despite positive news and promising GLP-1 drug developments. The biotech's oral GLP-1 candidate VK2735 showed impressive weight loss results and tolerability, with potential advantages over current weekly injectable treatments. Concerns about manufacturing costs and scalability exist, but Viking's strong pipeline and market potential in obesity make it a compelling investment. |
seekingalpha.com |
2024-12-19 12:30:00 |
Czytaj oryginał (ang.) |
| Here's Why VKTX Stock Plummeted 18% on Wednesday |
The selloff in Viking Therapeutics stock comes after some investors raised concerns for the small biotech amid Merck's entry into the obesity space. |
zacks.com |
2024-12-19 10:46:23 |
Czytaj oryginał (ang.) |